Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024

Inclusion on list recognizes Poseida for employee sentiment and satisfaction

SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced its inclusion in Newsweek Magazine's annual America's Top Most Loved Workplaces^® list, developed by Most Loved Workplace^®, a division of Best Practice Institute (BPI).

"At Poseida, our employees are essential to achieving our mission to boldly develop a new class of cell and gene therapies with the capacity to cure," said Kristin Yarema, Ph.D., president and chief executive officer of Poseida Therapeutics. "This recognition is a testament to our outstanding and exceptionally talented team at Poseida. It is an honor to be named to Newsweek's list of top workplaces, which reflects our strong culture and values combined with our commitment to our employees, as well as patients."

The results were determined after surveying more than 2.6 million employees from businesses with workforces varying in size from less than 50 to more than 10,000. The list recognizes companies that put respect, caring, and appreciation for their employees at the center of their business model and, in doing so, have earned the loyalty and respect of the people who work for them. 

How positive employees feel about their future at the company, career achievement, how much employer values align with employee values, respect at all levels, and the level of collaboration at the firm were the five critical areas measured to gauge employee sentiment. In addition, areas such as inclusion, diversity, equity and belonging, career development, and company leadership were identified and analyzed in relation to the five critical areas measured.

"It's inspiring to see the list expand this year to 200 companies, a clear indication that organizations are truly committed to creating workplaces where employees feel valued and connected. We're thrilled to celebrate their achievements as this recognition continues to grow," said Nancy Cooper, Newsweek's Global Editor in Chief.

This marks the fourth annual Most Loved Workplace list, and for 2024, the list has expanded to the Top 200, reflecting companies' growing commitment to prioritizing employee sentiment and creating workplaces that employees love. Poseida was ranked #140 on the list. For the full list of the 2024 America's Top 200 Most Loved Workplaces^®, please visit Newsweek.

Methodology
To identify the top 200 companies in this list, companies were evaluated and scored as follows: 50 percent of the initial score was based on direct employee responses to BPI's Love of Workplace Index assessment. 35 percent came from BPI's direct interviews and written responses from company officials. The final 15 percent was derived from analysis of external public ratings from sites such as Comparably, Careerbliss, Glassdoor, Indeed, and Google. Newsweek then conducted editorial research on every company before the final list of 200 companies and their rankings was completed.

About Newsweek
Newsweek is the modern global digital news organization built around the iconic, over 90-year-old American magazine. Newsweek reaches 100 million people each month with its thought-provoking news, opinion, images, graphics, and video delivered across a dozen print and digital platforms. Headquartered in New York City, Newsweek also publishes international editions in EMEA and Asia.

About Best Practice Institute
Best Practice Institute is an award-winning leadership and organization development center, benchmark research company, think tank, and solutions provider. BPI is the only certifying body for Most Loved Workplace^® and conducted the original research to create the model and criteria for becoming a Most Loved Workplace^®. BPI's research proves that Most Loved Workplaces^® produce 3-4 times better customer service, employee performance, and retention than companies not loved by their employees. 

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac^® DNA Delivery System, Cas-CLOVER^™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com and connect with Poseida on X and LinkedIn.

SOURCE Poseida Therapeutics, Inc.